cardiologists
	diabetologists
	endocrinologists
	primary care physicians
	psychiatrists
	urologists
	allied healthcare professionals

These healthcare professionals share an active interest in developing and participating in a variety of educational and interactive programs designed to enhance the clinical outcomes of ED therapy.

CIEF offers this wide array of certified continuing medical education (CME/CE) programs, and fosters collegial interaction to ensure that all its members are informed of the latest research and cutting-edge clinical treatments for ED.

Objectives

To achieve its mission, CIEF works closely with a multidisciplinary steering committee, as well as its members, to identify and respond to the evolving educational needs of all healthcare practitioners concerned with ED therapy.

To this end, CIEF engages in activities that will:

	Create greater awareness of ED as a ubiquitous disease affecting total health and quality of life for ED patients and partners; correlate the presence of ED with micro/macrovascular disease and establish that ED is prognostic for CVD
	Heighten sensitivity to and awareness of ED diagnosis by healthcare practitioners; provide strategies and tools to enable practitioners to elicit comments from patients regarding ED, and to provide appropriate patient counseling
	List the current treatments for ED; discuss, in particular, the use of orally active PDE5 inhibitors; review efficacy outcome measurements, in a clinically relevant way, from published clinical trials on treatment of ED with PDE5s
	Identify potential obstacles to current PDE5 treatment and explore the real-world effectiveness (including efficacy in multiple patient populations, onset of action, duration of effect, drug-drug/drug-food interactions), safety, and other considerations for successful treatment with PDE5 agents
	Review the physiology of normal male sexual arousal and penile erection (including the role of PDE5 therein); reconfirm that sexual stimulation is necessary for arousal and penile erection, even when using a PDE5, and establish that an important goal of treatment should be to "normalize" erectile function and sexual activity in this manner
	Compare the pathway selectivity of current PDE5 inhibitors, and identify how these variables may impact hemodynamics and other safety issues, as well as treatment outcomes
	Convey the high record of safety exhibited by PDE5 inhibitors — that adverse events are generally transient and mild to moderate in intensity, that the use of organic nitrates is the only contraindication, and that this contraindication is consistent across the entire class of drugs